Safety and Preliminary Activity of Neoadjuvant Trastuzumab Deruxtecan plus 5-Fluorouracil and Folinic Acid for HER2-Positive, Resectable Esophagogastric Adenocarcinoma: Results from the Safety Run-In Cohort of the Phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART Trial

Oncology Research and Treatment · Published 2026-05-29 · DOI 10.1159/000552693

Free full text

Authors (11)

Gertraud Stocker, Jack Chater, Thomas J. Ettrich, Thorsten O. Goetze, Reinhard U. Lindig, Sylvie Lorenzen, Alexander Stein, Sabine Junge, Claudia Pauligk, Salah-Eddin Al-Batran, F. Lordick

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Stocker, G., Chater, J., Ettrich, T., et al. (2026). Safety and Preliminary Activity of Neoadjuvant Trastuzumab Deruxtecan plus 5-Fluorouracil and Folinic Acid for HER2-Positive, Resectable Esophagogastric Adenocarcinoma: Results from the Safety Run-In Cohort of the Phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART Trial. Oncology Research and Treatment. https://doi.org/10.1159/000552693

Related articles